Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,068.75 Consensus Price Target from Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is GBX 2,068.75 ($25.55).

HIK has been the topic of a number of recent research reports. Barclays reaffirmed an “equal weight” rating and issued a GBX 2,000 ($24.70) target price on shares of Hikma Pharmaceuticals in a report on Monday, April 8th. Berenberg Bank lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.21) to GBX 2,000 ($24.70) and gave the company a “hold” rating in a report on Monday, February 26th.

Hikma Pharmaceuticals Stock Up 0.2 %

HIK stock opened at GBX 1,822 ($22.50) on Wednesday. The company’s 50 day moving average is GBX 1,895.12 and its two-hundred day moving average is GBX 1,871.48. The stock has a market cap of £4.04 billion, a P/E ratio of 2,714.93, a PEG ratio of 2.38 and a beta of 0.45. Hikma Pharmaceuticals has a twelve month low of GBX 1,711 ($21.13) and a twelve month high of GBX 2,222 ($27.45). The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st will be paid a $0.47 dividend. This is a boost from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. The ex-dividend date is Thursday, March 21st. Hikma Pharmaceuticals’s payout ratio is currently 8,507.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.